이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Molecular Templates 배당금

배당금 기준 확인 0/6

Molecular Templates 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.9%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$2.79
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Apr 03

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Dec 20

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Apr 17

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Nov 16

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Aug 14

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Aug 11

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Apr 29

News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Aug 15

Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

May 18

Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Mar 21

Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Feb 21

Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Jan 26

Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21

Dec 22

Here's What We Think About Molecular Templates' (NASDAQ:MTEM) CEO Pay

Dec 04

Molecular Templates: Progress Stalled As Partial Hold Placed On Pivotal ETB Trial

Nov 17

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 MTEM 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: MTEM 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Molecular Templates 시장 대비 배당 수익률

MTEM 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (MTEM)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.9%
3년 후 애널리스트 예측 (MTEM)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MTEM 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MTEM 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MTEM 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: MTEM 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Molecular Templates 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

New major risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting

Consensus revenue estimates decrease by 44%, EPS upgraded

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Market cap size

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Molecular Templates, Inc. Announces Board Changes

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Consensus revenue estimates increase by 16%

New major risk - Financial position

Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc. Announces the Appointment of Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

New major risk - Revenue and earnings growth

Molecular Templates Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Molecular Templates, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

Molecular Templates, Inc. announced that it expects to receive $40.044 million in funding from BVF Partners L.P., Adage Capital Management, L.P., Bellevue Asset Management AG

New major risk - Financial position

Consensus revenue estimates decrease by 16%, EPS upgraded

Molecular Templates, Inc. Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

Price target decreased by 67% to US$3.50

Consensus revenue estimates increase by 384%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Consensus revenue estimates decrease by 34%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 22% to US$10.13

Insufficient new directors

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Molecular Templates, Inc. Announces CFO Changes

Consensus revenue estimates increase by 13%

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to US$10.13

Molecular Templates Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Molecular Templates, Inc.(NasdaqGS:MTEM) dropped from Russell 2000 Dynamic Index

Price target decreased to US$9.33

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Price target decreased to US$10.92

Consensus forecasts updated

Price target decreased to US$10.92

Price target decreased to US$11.25

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Molecular Templates, Inc. Announces Management Appointments

Molecular Templates, Inc. Announces Management Appointments

Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Insufficient new directors

Price target decreased to US$11.57

Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.47 loss in 3Q 2020)

Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

Price target decreased to US$13.43

News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Second quarter 2021 earnings released: US$0.28 loss per share (vs US$0.68 loss in 2Q 2020)

CFO, Treasurer & Secretary Adam Cutler has left the company

Consensus revenue estimates fall to US$38.8m

Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.51 loss per share (vs US$0.48 loss in 1Q 2020)

Molecular Templates, Inc. Expects to Generate Clinical Data

Price target decreased to US$15.75